Potential for conflict of interest in the evaluation of suspected adverse drug reactions: a counterpoint.
Strom
Brian L
BL
Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia 19104-6021, USA. bstrom@cceb.med.upenn.edu
D016907:Adverse Drug Reaction Reporting Systems; D016265:Conflict of Interest; D017277:Drug Approval; D004345:Drug Industry; D004347:Drug Interactions; D015248:Gemfibrozil / Q000009:adverse effects; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents / Q000009:adverse effects; D011725:Pyridines / Q000009:adverse effects; D012206:Rhabdomyolysis / Q000139:chemically induced; D012306:Risk; D014481:United States; D014486:United States Food and Drug Administration
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D011725:Pyridines; C086276:cerivastatin; D015248:Gemfibrozil